Analytics
Resolved Yes on 19 Jun 2025.
The last daily price before settlement had Yes at 66.5%. Yes opened at 64% on 18 Jun 2025. Before it settled, across the 2 daily closes on record from 18 Jun 2025 to 19 Jun 2025, the highest close was 66.5% on 19 Jun 2025 and the lowest 64% on 18 Jun 2025. $2.35K traded over the market's life.
Polymarket record as of Jun 21, 12:26 AM UTC
Daily closes of the Yes price, Polymarket CLOB, 2 points, 18 Jun 2025 – 19 Jun 2025, chart shows 60%–72%
| Observed | Yes price |
|---|---|
| 18 Jun 2025 | 64.0% |
| 19 Jun 2025 | 66.5% |
Polymarket lists no holders for this market.
Open a trader’s name to inspect the wallet’s available P&L, positions and recorded trades, with source dates and coverage. A large position alone does not establish a winning track record.
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Gilead Sciences’ new biologics license application (BLA) for lenacapavir as a treatment for Human Immunodeficiency Virus (HIV) by June 19, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No." This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Official listing: polymarket.com/event/fda-approves-gileads-lenacapavir-for-treating-hiv-human-immunodeficiency-virus
New to prediction markets? How to read a market page
